LONDON, April 24, 2006 – KGK Synergize Inc., a life science product development and contract research business focused on nutraceuticals, today announced it has retained Janus Corporate Finance to act as principal financial advisor in arranging additional growth capital for its emerging nutraceutical product technologies.
“Our three most recently emerging science-based nutraceutical product groups, each moving along their rigorous pathways to commercialization, are going to bring significant health benefits to many of those suffering from, or concerned about the on-set of, Type II Diabetes; to consumers worried about Melanoma and the damaging effects of the sun on their skin; and to those seeking to protect themselves from developing Prostate, Colon and Skin Cancers” advised CEO and co-founder, Najla Guthrie.
“Getting these new, patent-pending nutraceutical products into consumers’ hands safely and quickly will require more capital than KGK can generate internally from our profitable contract research business and growing royalties from Sytrinol(TM), our first commercialized product” Ms. Guthrie added; “and as a result, we have retained Janus Corporate Finance, who arranged our first successful private placement in 2004, to assist us in attracting investors for our current financing needs.”
KGK’s core areas of expertise are focused on providing preventative and/or treatment solutions for Cardiovascular Health (including cholesterol management) Type II Diabetes, Skin-Care & Anti-Aging as well as some forms of Cancer utilizing scientifically proven nutraceutical product technologies. To date, the Company has received 3 US and international patents with more than 20 patent applications pending.
The Company’s first product to be commercialized is Sytrinol, a patented and clinically proven cholesterol-lowering nutraceutical formulation, currently under exclusive license to a US based marketing and distribution firm as a dietary supplement. Now emerging from KGK’s product pipeline are 3 more patent-pending nutraceutical product technologies focused on Type II Diabetes prevention, Skin-Care & Anti-Aging enhancements, as well as a natural preventative for some forms of Prostate, Colon and Skin Cancers.
“KGK is a well run, science-oriented business whose principal product technologies are positioned to stand the scrutiny of evolving regulatory pressure on nutraceutical product safety and efficacy”, said Michael Walker, President of Janus Corporate Finance; “and we believe that this is consistent with the investment criteria of many of the most professional investors in the life sciences sector”.
Janus Corporate Finance, an affiliate of JR/Janus Merchant Brokers Ltd., has been in business since 1987 offering corporate finance and investment banking advisory services to mid-sized corporations, management and investor groups, as well as private and family businesses.
- 30 -
For further information, contact: